Cowen analyst Eric Schmidt weighed in on Amgen (NASDAQ: AMGN) after the highly anticipated FOURIER CV outcomes data details were ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE